BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Griffin AM, Kahlig KM, Hatch RJ, Hughes ZA, Chapman ML, Antonio B, Marron BE, Wittmann M, Martinez-Botella G. Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series. ACS Med Chem Lett 2021;12:593-602. [PMID: 33859800 DOI: 10.1021/acsmedchemlett.0c00675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 M Qunies A, A Emmitte K. Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies. Pharm Pat Anal 2022. [PMID: 35369761 DOI: 10.4155/ppa-2022-0002] [Reference Citation Analysis]
2 Cole BA, Clapcote SJ, Muench SP, Lippiat JD. Targeting KNa1.1 channels in KCNT1-associated epilepsy. Trends Pharmacol Sci 2021;42:700-13. [PMID: 34074526 DOI: 10.1016/j.tips.2021.05.003] [Reference Citation Analysis]